Remedee Labs
Montbonnot-saint-martin
About Remedee Labs
1.5 billion people worldwide suffer from chronic pain and over half of them are not satisfied with their care. Remedee Labs aims to give these patients a new life. Based on 10 years of pre-clinical and clinical research, Remedee Labs has developed the first endorphin stimulator for personal use. Building on the experience of its clinical partners, the company now uses its unique technology to offer the first patient-centered digital service platform for chronic pain management, working alongside medical practitioners. Remedee Labs initial focus is helping patients with fibromyalgia, and plans extend the Platform offering to other chronic pain conditions in the coming future. Founded in 2016, Remedee Labs announced in 2019 that it had raised 12 million dollard from investors, including HCVC, Habert Dassault Finance, Partech, Supernova Invest and C4 Venture.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $24.8M
- Funding stage: Early Stage Venture
- Last round: Series A (Dec 2022)
- Website: remedeelabs.com
- Phone: [email protected]
Industries & Categories
Health Care, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/remedee-labs-112150 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.